Clinical Trial: Dovitinib in Adenoid Cystic Carcinoma
Study Status: Completed
Recruit Status: Completed
Study Type: Interventional
Official Title: Phase II Study of TKI258 (Dovitinib) Monotherapy in Patients With Unresectable Adenoid Cystic Carcinoma
Brief Summary: The purpose of this phase II study of TKI258 (Dovitinib) in adenoid cystic carcinoma is to evaluate the efficacy of TKI258 (Dovitinib).
Detailed Summary: open, uncontrolled, multi-center, phase II study
Sponsor: Seoul National University Hospital
Current Primary Outcome: progression free survival [ Time Frame: 4 month ]
Original Primary Outcome: Same as current
Current Secondary Outcome:
- overall survival [ Time Frame: 2 years ]
- response rate [ Time Frame: 8 weeks ]CT scan will be evaluated every 2 cycles (per 8 weeks)till progression. Reponse rate will be evaluated by RECIST criteria
Original Secondary Outcome: Same as current
Information By: Seoul National University Hospital
Dates:
Date Received: August 9, 2011
Date Started: September 2011
Date Completion:
Last Updated: November 11, 2014
Last Verified: November 2014